Biotech Values

[BioSpecialist]

Cancer pain drug EU approval in Jan 2008

very attractive stock

Presentation:
http://www.orexo.com/graphics/14661.pdf

Homepage:
www.orexo.com

Orexo AB (ORX.ST)

Marketcap: 196 million US$
Cash: 38 million US$

Pipeline:
http://www.orexo.com/DynPage.aspx?id=14917&mn1=1542


Rapinyl (Cancer Pain) Phase III / US-NDA in 1H 2008
Rapinyl (Cancer Pain) Registration phase in EU

Sublinox (Insomnia)complete positive phase III /US- NDA in Jan 2008

OX 17 (GERD-gastro esophageal reflux disease) Phase III results in 1H 2008 US /EU --Blockbuster Potential

BLX-NLA (Rhinitis) start Phase III in 1H 2008


http://www.orexo.com/DynPage.aspx?id=17488&pid=154120
Orexo´s Rapinyl nearing regulatory decision in Europe
[2007-09-28 8:00]

Orexo´s European licensing partner ProStrakan Group plc, for the cancer breakthrough pain product Rapinyl on the European market, today announced that Rapinyl will be referred for review by the Committee for Medicinal Products for Human Use (CHMP) of the EMEA. Of the 25 member states involved in the EU Decentralised Procedure (DCP) for Rapinyl, 21 consider this product to be approvable.


Anticipated news flow until the end of 2008
• Short term cash generating and pipeline value enhancing
business development

– EU approval and launch of Rapinyl
– Partnering agreement OX-17
– NLA Nasal Spray partnering agreement
– Partnering agreement Sublinox
– Partnering agreement dual effect respiratory drug and EOXIN inhibitor

• Product development
– FDA filing of Sublinox
– EU approval and launch of Rapinyl
– FDA filing of Rapinyl in the US
– Initiation Phase II PDE4 inhibitor in asthma and COPD
– Initiation Phase I EOXIN inhibitor in asthma
– First Phase II data PDE4 inhibitor
– Phase I data EOXIN inhibitor in asthma